Real-World Impact of Mepolizumab in COPD in a US Commercial and Medicare Claims Database.
8 affiliations
- 1Rutgers Institute for Translational Medicine and Science, The State University of New Jersey, New Brunswick, NJ, USA.
- 2Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
- 3Global Real-World Evidence and Health Outcomes Research, GSK, Collegeville, PA, USA.
- 4US Medical Affairs, R&D Global Medical, GSK, Durham, NC, USA.
- 5Groupe d'analyse SRI, Montréal, QC, Canada.
- 6US Medical Affairs, GSK, Collegeville, PA, USA.
- 7Analysis Group, Ltd, Boston, MA, USA.
- 8Division of Pulmonary Diseases/Critical Care Medicine, University of Texas Health, San Antonio, TX, USA.
Abstract
Purpose
Mepolizumab reduces exacerbations in patients with chronic obstructive pulmonary disease (COPD) and was recently approved in the United States (US) for the add-on maintenance treatment of adult patients with inadequately controlled COPD and an eosinophilic phenotype. Given the limited real-world data on mepolizumab effectiveness in COPD, this study assessed its real-world impact in patients with COPD, prior to US regulatory approval of mepolizumab for COPD.Patients and methods
Retrospective, longitudinal analysis from the US Komodo Research claims database (January 2016-June 2024). The first observed mepolizumab claim was defined as the index date. All patients were aged ≥40 years on index date, had ≥2 COPD diagnosis claims in the 12 months pre-index (baseline period) or on index date, and required ≥2 pharmacy/medical claims for mepolizumab from index date to end of observation. Patients with ≥2 asthma diagnosis claims or ≥1 diagnosis claim(s) for cystic fibrosis, lung cancer, interstitial lung disease, or α-1 antitrypsin deficiency during the baseline period or on index date were excluded. Outcomes assessed during the 12 months post- versus 12 months pre-mepolizumab initiation included annualized exacerbation rates, oral corticosteroid (OCS) use, and COPD-related healthcare resource utilization (HCRU).Results
Descriptive analyses included 693 mepolizumab initiators (58% Medicare), while pre-post analyses included 470 patients with 12 months of pre- and post-initiation data. Annualized rate of moderate/severe exacerbations decreased by 41% (P<0.001) post- versus pre-mepolizumab. Relative reductions of 26% and 33% in rates of OCS dispensing and bursts were observed (P<0.001), and relative reductions of 22-37% in COPD-related HCRU including hospitalizations (P=0.038), emergency department visits (P<0.001), and outpatient visits (P<0.001).Conclusion
In this real-world retrospective study of US patients with COPD, initiation of mepolizumab was associated with significant reductions in COPD exacerbations, OCS use and COPD-related HCRU.
Related
- What Medicare Claims Tell Us About Cancer Disparities in American Indian and Alaska Native Peoples
- Antihypertensive Medication Class and Incident Alzheimers Disease and Related Dementias: External Replication Across Two Independent Healthcare Data Sources-the Vanderbilt EHR Synthetic Derivative and US Medicare Claims
- Performance of Claims-based Alzheimer’s Disease and Related Dementias Algorithms in Medicare Advantage and Fee-for-Service Populations
- Patient-Provider Distance in Medicare Outpatient Oncology Telehealth Versus Office Visits, 2021-2023: Cross-Sectional Claims Analysis.
- Claims-Based Phenotyping of Acute Kidney Transplant Rejection in a National Medicare Cohort.
BibTeX
@article{panettieri2026realworld,
title = {{Real-World Impact of Mepolizumab in COPD in a US Commercial and Medicare Claims Database.}},
author = {Reynold A Panettieri and Rosirene Paczkowski and Hannah Mei and Emmeline Burrows and Guillaume Germain and Sunay Shah and Jacob Klimek and Sophie Ma and Sarah Cooper and François Laliberté and Antonio Anzueto},
journal = {International journal of chronic obstructive pulmonary disease},
year = {2026},
month = oct,
doi = {10.2147/copd.s623966},
url = {https://europepmc.org/article/MED/42928917},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Real-World Impact of Mepolizumab in COPD in a US Commercial and Medicare Claims Database.
AU - Reynold A Panettieri
AU - Rosirene Paczkowski
AU - Hannah Mei
AU - Emmeline Burrows
AU - Guillaume Germain
AU - Sunay Shah
AU - Jacob Klimek
AU - Sophie Ma
AU - Sarah Cooper
AU - François Laliberté
AU - Antonio Anzueto
PY - 2026
DA - 2026/10/21
JO - International journal of chronic obstructive pulmonary disease
DO - 10.2147/copd.s623966
UR - https://europepmc.org/article/MED/42928917
AB - Purpose Mepolizumab reduces exacerbations in patients with chronic obstructive pulmonary disease (COPD) and was recently approved in the United States (US) for the add-on maintenance treatment of adult patients with inadequately controlled COPD and an eosinophilic phenotype. Given the limited real-world data on mepolizumab effectiveness in COPD, this study assessed its real-world impact in patients with COPD, prior to US regulatory approval of mepolizumab for COPD.Patients and methods Retrospective, longitudinal analysis from the US Komodo Research claims database (January 2016-June 2024). The first observed mepolizumab claim was defined as the index date. All patients were aged ≥40 years on index date, had ≥2 COPD diagnosis claims in the 12 months pre-index (baseline period) or on index date, and required ≥2 pharmacy/medical claims for mepolizumab from index date to end of observation. Patients with ≥2 asthma diagnosis claims or ≥1 diagnosis claim(s) for cystic fibrosis, lung cancer, interstitial lung disease, or α-1 antitrypsin deficiency during the baseline period or on index date were excluded. Outcomes assessed during the 12 months post- versus 12 months pre-mepolizumab initiation included annualized exacerbation rates, oral corticosteroid (OCS) use, and COPD-related healthcare resource utilization (HCRU).Results Descriptive analyses included 693 mepolizumab initiators (58% Medicare), while pre-post analyses included 470 patients with 12 months of pre- and post-initiation data. Annualized rate of moderate/severe exacerbations decreased by 41% (P<0.001) post- versus pre-mepolizumab. Relative reductions of 26% and 33% in rates of OCS dispensing and bursts were observed (P<0.001), and relative reductions of 22-37% in COPD-related HCRU including hospitalizations (P=0.038), emergency department visits (P<0.001), and outpatient visits (P<0.001).Conclusion In this real-world retrospective study of US patients with COPD, initiation of mepolizumab was associated with significant reductions in COPD exacerbations, OCS use and COPD-related HCRU.
SN - 1176-9106
SN - 1178-2005
ER -